Archive
All News
Every briefing, headline, and filing we've published, newest first.
The WeekDrug Channels ↗
By Adam J. Fein, Ph.D. and Greis Kapexhiu In late June, the boffins at the Centers for Medicare & Medicaid Ser…
The WeekSTAT News ↗
Kennedy and Oz say Medicaid isn't being cut. But state Medicaid directors say new policies are likely to cause…
The WeekBioPharma Dive ↗
In fact, the former lost tens of billions of dollars in market value following reports of a tie-up between the…
The WeekPharmaVoice ↗
The president's most recent tariff proposal gives pharma more time to transition its global supply chain and r…
The WeekFiercePharma ↗
Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, co…
The WeekFierceBiotech ↗
Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, co…
The WeekBriefing
Three Asia-linked developments stood out: a CEO exit at Legend, a quickly deleted Merck trial posting, and an …
The WeekPharmaVoice ↗
How Evonik is shaping more sustainable oral drug delivery through data and excipient innovation.…
The WeekPharmaceutical Technology ↗
Ratio Therapeutics, a US-based developer of radiopharmaceuticals for cancer treatment, has closed a $70m Serie…
The WeekSTAT News ↗
Educators want future physicians to be fluent in AI scribes, but they worry what off-loading clinical notes to…
The WeekFiercePharma ↗
Reporting a new miss in one indication, Karyopharm is plowing ahead with plans to advance its XPO1 inhibitor X…
The WeekFierceBiotech ↗
Whether it's looming tariff threats or the rise of China, you need a truly global view to navigate today's bio…
The WeekBriefing
AbbVie’s Skyrizi generated $5.55 billion in second-quarter sales, nearly matching Humira’s best quarter. The r…
The WeekFiercePharma ↗
A Daiichi Sankyo quarterly report that should have celebrated strong commercial execution was instead derailed…
The WeekFierceBiotech ↗
Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was…
The WeekBriefing
Novartis’ Pluvicto won FDA approval on July 31 for use with ARPI therapy in PSMA-positive metastatic androgen …
The WeekFiercePharma ↗
Amylyx's patient education website aims to empower patients to navigate post-bariatric hypoglycemia (PBH), a r…
The WeekFierceBiotech ↗
A phase 3 trial of Novo Nordisk's ziltivekimab has missed its primary endpoint, denting the prospects of a mol…
The WeekBriefing
FiercePharma’s “The Top Line” highlighted three pressure points this week: M&A in psychedelics, peptide re…
The WeekSTAT News ↗
The Trump administration is revising its rebate pilot for the 340B drug discount program, angering hospitals.…
The WeekBioPharma Dive ↗
Ziltivekimab's failure in a key trial spurred share sell-offs for Novo and other biotechs, as it suggested tro…
The WeekBioPharma Dive ↗
Sanofi wants to broaden the company's productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol…
The WeekSTAT News ↗
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmace…
The WeekPharmaVoice ↗
Early-stage candidates, mid-sized companies and of course, Chinese assets, are dominating the dealmaking pictu…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.